Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.

Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J
J Clin Oncol. 1993 11 (8): 1496-505

PMID: 8336188 · DOI:10.1200/JCO.1993.11.8.1496

MeSH Terms (14)

Adult Aged Carcinoma, Renal Cell Female Humans Injections, Intravenous Interleukin-2 Leukocyte Count Male Melanoma Middle Aged Muromonab-CD3 Receptors, Interleukin-2 T-Lymphocytes

Connections (1)

This publication is referenced by other Labnodes entities:

Links